FDA Issues Urgent Recall for Multiple Cough Drop Products
The U.S. Food and Drug Administration (FDA) has announced a significant recall affecting more than a dozen varieties of cough drops due to undisclosed quality concerns. The voluntary recall was initiated by China-based manufacturer Xiamen Kang Zhongyuan Biotechnology Co., Ltd. following an FDA inspection in August 2025 that revealed observations potentially impacting product quality.
Scope and Details of the Recall
The recall encompasses 15 distinct cough drop products, all containing menthol—a natural compound derived from mint oils known for providing throat-soothing relief through a cooling sensation. While the exact number of affected lots remains unspecified, the products were distributed in various packaging sizes including 25-, 30-, 80-, and 90-count bags. These items carry expiration dates ranging from May through October 2026.
The FDA has classified this as a Class II recall, indicating a situation where product use might lead to temporary or medically reversible adverse health effects, though the probability of serious consequences is considered remote. Importantly, no illnesses or adverse reactions have been reported to date in connection with these products.
Understanding Quality Issues
When the FDA references "product quality issues" in recall contexts, this typically signifies failures to meet established safety, manufacturing, or labeling standards that could potentially endanger consumers. Such deficiencies might involve contamination risks from bacteria, fungi, or foreign materials due to facility conditions. Additional concerns could include malfunctioning equipment or unsanitary production environments.
Despite the recall action, the FDA has not yet issued a warning letter to Xiamen Kang Zhongyuan Biotechnology regarding their facility inspection findings. The agency has also not provided specific guidance for consumers who may have purchased the affected cough drops.
Recent Recall Context
This cough drop recall represents the latest in a series of medication and supplement withdrawals from the market. Earlier this week, regulators announced the recall of over 350,000 bottles of iron supplements due to inadequate child-resistant packaging. Last month, Strides Pharma, Inc. recalled nearly 90,000 bottles of children's ibuprofen suspension following consumer complaints about foreign substances in the medication, including gel-like masses and black particles.
Recalled Product Details
The affected cough drops include multiple brands and formulations:
- exchange select menthol cough drops in honey lemon and menthol flavors
- caring mill cherry-flavored cough drops
- Discount Drug Mart Food Market cough drops in honey lemon and standard menthol varieties
- MGC Health sugar-free honey lemon and regular honey lemon cough drops
- QC Quality Choice products in multiple flavors including black cherry, honey lemon, menthol, creamy strawberry, and vanilla honey
All recalled items share the common manufacturing origin of Xiamen Kang Zhongyuan Biotechnology in China and were distributed through various U.S. companies. The recall was prompted specifically by observations noted during the FDA's August 15, 2025 facility inspection that may bear on product quality standards.
